2. Disease Areas
  3. Neurological, Eye or Ear Disease Inflammation or Immune System Disease
  4. CNS Infection Autoimmune Disease
  5. Experimental Autoimmune Encephalomyelitis

Experimental Autoimmune Encephalomyelitis

Experimental autoimmune encephalomyelitis (EAE), is an animal model of brain inflammation. It is an inflammatory demyelinating disease of the central nervous system (CNS). It is mostly used with rodents and is widely studied as an animal model of the human CNS demyelinating diseases, including multiple sclerosis (MS) and acute disseminated encephalomyelitis (ADEM). EAE is also the prototype for T-cell-mediated autoimmune disease in general.

Experimental Autoimmune Encephalomyelitis (86):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N1423
    Glycocholic acid 475-31-0 99.90%
    Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).
    Glycocholic acid
  • HY-B1659
    Glycerol 56-81-5 99.99%
    Glycerol is used in sample preparation and gel formation for polyacrylamide gel electrophoresis.
    Glycerol
  • HY-124617A
    AMXT-1501 tetrahydrochloride 2444815-84-1 98.0%
    AMXT-1501 tetrahydrochloride is a Bacterial agent and polyamine transport system inhibitor. AMXT-1501 tetrahydrochloride targets membrane phospholipids and exhibits antibacterial activity against a variety of Gram-positive and Gram-negative multidrug-resistant bacteria. AMXT-1501 tetrahydrochloride inhibits capsular biosynthesis in Streptococcus pneumoniae. AMXT-1501 tetrahydrochloride targets ornithine decarboxylase and polyamines to inhibit the proliferation of neuroblastoma cells. AMXT-1501 tetrahydrochloride in combination with DFMO (HY-B0744) induces Apoptosis in neuroblastoma cells. AMXT-1501 tetrahydrochloride is applicable to research related to multidrug-resistant bacterial infections, pneumococcal infections, Streptococcus pneumoniae infections, and neuroblastoma.
    AMXT-1501 tetrahydrochloride
  • HY-109192
    Tolebrutinib 1971920-73-6 99.12%
    Tolebrutinib (SAR442168) is an orally active, selective, and blood-brain barrier-penetrant BTK inhibitor with neuroactive properties. Tolebrutinib is being investigated for use in multiple sclerosis (MS), particularly secondary progressive multiple sclerosis (SPMS)..
    Tolebrutinib
  • HY-12355
    Siponimod 1230487-00-9 99.95%
    Siponimod (BAF-312) is an orally active, blood-brain barrier penetrant dual agonist of S1P1/S1P5, with EC50 values of 0.39 nM and 0.98 nM, respectively. Siponimod induces S1P1 internalization, activates GIRK channels, inhibits lymphocyte egress, reduces peripheral lymphocyte counts, triggers transient bradycardia, prevents synaptic neurodegeneration, promotes remyelination, alleviates demyelination, and prevents the loss of GABAergic interneurons. Siponimod can be used in research related to multiple sclerosis.
    Siponimod
  • HY-156458A
    (R)-SR-29065 2756883-91-5
    (R)-SR-29065 is a selective REV-ERBα inhibitor with a IC50 of 10 nM. (R)-SR-29065 is applicable to research related to autoimmune diseases.
    (R)-SR-29065
  • HY-A0251A
    Cefpodoxime sodium 82619-04-3
    Cefpodoxime (R 3763) sodium is a potent antibiotic active against gram-positive and gram-negative bacteria. Cefpodoxime inhibits the majority of cells in microbial populations. Cefpodoxime sodium can be used for acute otitis media, sinusitis and tosillopharyngitis research.
    Cefpodoxime sodium
  • HY-179502
    Anti-inflammatory agent 107
    Anti-inflammatory agent 107 is an orally active anti-inflammatory agent. Anti-inflammatory agent 107 inhibits and NF-κB with a superior binding affinity of -9.4578 kcal/mol. Anti-inflammatory agent 107 reduces levels of inflammatory biomarkers (TNF-α, IL-6, INF-γ, NF-κβ, C-reactive protein and Erythrocyte Sedimentation Rate) and enhances the endogenous antioxidant defense system by elevating SOD (Superoxide Dismutase), CAT (Catalase) and GSH (Glutathione) activities. Anti-inflammatory agent 107 not induces liver toxicity and demonstrates hepatoprotective effects. Anti-inflammatory agent 107 dose-dependently ameliorates leukocyte infiltration and tissue edema. Anti-inflammatory agent 107 can be used for anti-inflammatory research.
    Anti-inflammatory agent 107
  • HY-P99568
    Telitacicept 2136630-26-5 99.30%
    Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease. The component ratio of this product is Active ingredient : Excipients = 1: 0.5-1: 0.8.
    Telitacicept
  • HY-Y0344D
    Sodium chloride, for cell culture 7647-14-5 99.9%
    Sodium chloride, for cell culture is an orally active salt. Sodium chloride, for cell culture induces the expression of ATP1A1. Sodium chloride, for cell culture induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, for cell culture enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, for cell culture drives autoimmune disease by the induction of pathogenic Th17 cells.
    Sodium chloride, for cell culture
  • HY-N6810
    Thymol 89-83-8 99.97%
    Thymol is a TRPA1 agonist. Thymol induces cancer cell apoptosis. Thymol is the main monoterpene phenol occurring in essential oils isolated from plants belonging to the Lamiaceae family, and other plants such as those belonging to the Verbenaceae, Scrophulariaceae, Ranunculaceae and Apiaceae families. Thymol has antioxidant, anti-inflammatory, antibacterial and antifungal effects.
    Thymol
  • HY-B1005
    8-Hydroxyquinoline 148-24-3 99.99%
    8-Hydroxyquinoline (8-Quinolinol) is a lipophilic metal chelator that can be used as a fungicide .8-Hydroxyquinoline shows the MIC range of 27.56-55.11 μM (4-8 μg/mL) against the clinical isolates of Neisseria gonorrhoeae. 8-Hydroxyquinoline can bind to copper form complexes and transport copper into cells. 8-Hydroxyquinoline increases in the number of micronucleated polychromatic erythrocytes and can also make hair depigmented in mice.
    8-Hydroxyquinoline
  • HY-N0681
    D-Pantothenic acid hemicalcium salt 137-08-6 99.80%
    D-Pantothenic acid hemicalcium salt is an orally active vitamin that reduces patulin in apple juice. D-Pantothenic acid hemicalcium salt removes ROS. D-Pantothenic acid hemicalcium salt has antibacterial and immunomodulatory activities. D-Pantothenic acid hemicalcium salt also has the effect of improving osteoporosis and obesity.
    D-Pantothenic acid hemicalcium salt
  • HY-P990008
    Atrosab 1365659-05-7 99.94%
    Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. Atrosab can be used for research of inflammatory disease. The recommend isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
    Atrosab
  • HY-108831
    Natalizumab 189261-10-7 99.10%
    Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4+ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses.
    Natalizumab
  • HY-N0610
    Trans-Cinnamic acid 140-10-3 99.98%
    trans-Cinnamic acid is a natural antimicrobial, with minimal inhibitory concentration (MIC) of 250 μg/mL against fish pathogen A. sobria, SY-AS1.
    Trans-Cinnamic acid
  • HY-108831A
    Natalizumab (Anti-CD49d) 189261-10-7 99.71%
    Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4+ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses.
    Natalizumab (Anti-CD49d)
  • HY-P991049
    Atrosimab 99%
    Atrosimab is an Fv-Fc1K fusion protein with an EC50 value of 0.37 nM against humans. Atrosimab inhibits TNF-induced TNFR1 activation, release of IL-6 and IL-8, and cell death, and alleviates neuroinflammation. Atrosimab is applicable to research related to inflammatory diseases, neurodegenerative diseases, acute and chronic inflammation, experimental arthritis, non-alcoholic steatohepatitis, and experimental autoimmune encephalomyelitis.
    Atrosimab
  • HY-B0987
    Ascorbyl palmitate 137-66-6 99.62%
    Ascorbyl palmitate is an orally active ester formed from ascorbic acid and palmitic acid, used as an antioxidant and food additive. Ascorbyl palmitate in preventing fat and oil oxidation is more efficient than Butylated hydroxyanisole (HY-B1066) and Butylated hydroxytoluene (HY-Y0172). Ascorbyl palmitate mitigates inhibition of collagen synthesis by select calcium and sodium channel blockers. Ascorbyl palmitate induces Apoptosis in human umbilical vein endothelial cells (HUVECs). Ascorbyl palmitate ameliorates inflammatory diseases by inhibition of NLRP3 inflammasome.
    Ascorbyl palmitate
  • HY-P99148
    Anti-Mouse/Rat/Rabbit TNF alpha Antibody (TN3-19.12) 99.24%
    Anti-Mouse TNF alpha Antibody (TN3-19.12) is an anti-mouse TNF alpha IgG antibody inhibitor derived from host Armenian Hamster. Anti-Mouse TNF alpha Antibody (TN3-19.12) neutralizes cytotoxic activity in supernatants obtained from LNC-8 cells. Anti-Mouse TNF alpha Antibody (TN3-19.12) reduces the symptoms and severity of EAE (experimental allergic encephalomyelitis) in LNC-8 cells xenograft mice models. Anti-Mouse TNF alpha Antibody (TN3-19.12) prevents diabetes in NOD mice. Anti-Mouse TNF alpha Antibody (TN3-19.12) shows apparent radiosensitizing effect in CD2F1 mice.
    Anti-Mouse/Rat/Rabbit TNF alpha Antibody (TN3-19.12)